TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01262053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Intervention
Description: The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders. For example, for a patient named Donald Duck who is 76 years old and male, the user will be required to type dd76m to unlock the order pad. This step will NOT be required for every order, but WILL be required every time the user enters the order pad (i.e. if a user leaves the order pad and then returns, the system will require the initials, age and sex to be re-entered as above). This will be a forcing function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Parallel control with no intervention
Study: NCT04153032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebo
Description: Moist exposed burn ointment (MEBO) is a tropical Chinese medicine composed of sesame oil and herbal plants that is clinically used for the treatment of burn wound.
Study: NCT01408004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Tablet 800mg qd til progression
Study: NCT01408004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: tablet 10 mg qd til progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
Study: NCT03218904

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose intake
Description: Experiment 1: study day1- single oral dose of glucose study day 2-single oral dose of glucose with U-13C-glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrates intake
Description: Experiment 2:study day1- single oral dose of uncooked cornstarch study day 2- single oral dose of Glycosade®
Study: NCT04408820

Intervention type: DRUG
Intervention: Roxadustat
Description: Oral
Study: NCT03992755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIQ861 Inhaled Treprostinil
Description: LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
Study: NCT02823028

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Web Guide
Description: A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web Guide
Description: A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules.
Study: NCT04646707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erector Spinae (ESP) Block with Lidocaine/Bupivacaine
Description: Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
Study: NCT02823028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Guide
Description: A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Guide
Description: A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules.
Study: NCT04646707

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erector Spinae (ESP) Block with placebo
Description: Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
Study: NCT02312960

Intervention type: OTHER
Group type: OTHER
Intervention: Data Collection
Description: No study treatment will be provided in this long term follow up study.
Study: NCT03861975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Cancer-Related Lymphedema Measurements
Description: All patients will receive bilateral arm measurements using the LymphaTech Scanner and the Perometer.
Study: NCT01534819

Intervention type: DEVICE
Intervention: EndoAnchor™
Description: Use of the EndoAnchor™ in conjunction with endograft

Intervention type: DEVICE
Intervention: EndoAnchor™
Description: Use of the EndoAnchor™ in conjunction with endograft

Intervention type: DEVICE
Intervention: EndoAnchor™
Description: Use of the EndoAnchor™ in conjunction with endograft

Intervention type: DEVICE
Intervention: EndoAnchor™
Description: Use of the EndoAnchor™ in conjunction with endograft

Intervention type: DEVICE
Intervention: EndoAnchor™
Description: Use of the EndoAnchor™ in conjunction with endograft

Intervention type: DEVICE
Intervention: EndoAnchor™
Description: Use of the EndoAnchor™ in conjunction with endograft

Intervention type: DEVICE
Intervention: EndoAnchor™
Description: Use of the EndoAnchor™ in conjunction with endograft

Intervention type: PROCEDURE
Intervention: endovascular treament
Description: implantation of a device inserted through an artery

Intervention type: PROCEDURE
Intervention: endovascular treament
Description: implantation of a device inserted through an artery

Intervention type: PROCEDURE
Intervention: endovascular treament
Description: implantation of a device inserted through an artery

Intervention type: PROCEDURE
Intervention: endovascular treament
Description: implantation of a device inserted through an artery

Intervention type: PROCEDURE
Intervention: endovascular treament
Description: implantation of a device inserted through an artery

Intervention type: PROCEDURE
Intervention: endovascular treament
Description: implantation of a device inserted through an artery

Intervention type: PROCEDURE
Intervention: endovascular treament
Description: implantation of a device inserted through an artery
Study: NCT02823028

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tweet2Quit
Description: A fully automated, 90-day quit smoking intervention that provides an online, peer-to-peer support group for quitting and uses twice-daily automessages to encourage and direct the peer-to-peer exchanges. Each group will consist of 12 buddy pairs (matched on key demographics) that will be introduced via automated texts. The program will generate twice-daily programmed contacts (e.g., what benefits do you hope to get from quitting smoking?). Automated pattern detection software will identify and address any problematic low tweeting within a group.
Study: NCT01294332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: supervised exercise on the treadmill at target heart rate range for 12 weeks, 3 times a week for 30 minutes.
Study: NCT04629677

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT03196011

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TKR with mechanical alignment method
Description: TKR implanted using traditional mechanical alignment methods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TKR with alternative alignment method
Description: TKR implanted using alternative alignment methods
Study: NCT04308174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Gem/Cis
Description: Neoadjuvant Durvalumab + Gemcitabine/Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gem/Cis
Description: Neoadjuvant Gemcitabine/Cisplatin
Study: NCT04294628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Given IV
Study: NCT06190340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 capsules
Description: Administration orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 capsules
Description: Administration orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 capsules
Description: Administration orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration orally.
Study: NCT01408004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
Study: NCT01259505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1
Description: CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study: NCT02324062

Intervention type: OTHER
Intervention: Questionnaires
Description: These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.

Intervention type: OTHER
Intervention: Questionnaires
Description: These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.

Intervention type: OTHER
Intervention: Questionnaires
Description: These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.

Intervention type: OTHER
Intervention: Blood Draw and Baseline Questionnaire
Description: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
Study: NCT04035005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg infusion every 24 weeks. A minimum interval of 20 or 22 weeks, depending if the previous dose was administered in one or two infusion, should be maintained between each infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The first dose of placebo will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, placebo will be administered as a single 600 mg infusion every 24 weeks, with a minimum interval of 20 or 22 weeks, depending if the previous dose was administered in one or two infusion, should be maintained between each infusion.
Study: NCT02823028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tweet2Quit
Description: A fully automated, 90-day quit smoking intervention that provides an online, peer-to-peer support group for quitting and uses twice-daily automessages to encourage and direct the peer-to-peer exchanges. Each group will consist of 12 buddy pairs (matched on key demographics) that will be introduced via automated texts. The program will generate twice-daily programmed contacts (e.g., what benefits do you hope to get from quitting smoking?). Automated pattern detection software will identify and address any problematic low tweeting within a group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tweet2Quit
Description: A fully automated, 90-day quit smoking intervention that provides an online, peer-to-peer support group for quitting and uses twice-daily automessages to encourage and direct the peer-to-peer exchanges. Each group will consist of 12 buddy pairs (matched on key demographics) that will be introduced via automated texts. The program will generate twice-daily programmed contacts (e.g., what benefits do you hope to get from quitting smoking?). Automated pattern detection software will identify and address any problematic low tweeting within a group.
Study: NCT03459846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV q4w
Study: NCT02324062

Intervention type: OTHER
Intervention: Blood Draw and Baseline Questionnaire
Description: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.

Intervention type: OTHER
Intervention: Blood Draw and Baseline Questionnaire
Description: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
Study: NCT03459846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for oral tablet BID
Study: NCT01371994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT02095873

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glyoxalase 1 (Glo1) inducer
Description: Dietary bioactive

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glyoxalase 1 (Glo1) inducer
Description: Dietary bioactive

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Mannitol, 108 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Mannitol, 108 mg
Study: NCT03968029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suturing meniscal augmented
Description: meniscal tear sutured + bone marrow injection/collagen membrane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suturing meniscal
Description: meniscal tear sutured
Study: NCT00053677

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Description: For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For subjects who were randomly assigned to placebo.
Study: NCT02143453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: 30 to 60-minute continuous exercise at 80% of the peak heart rate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
Study: NCT02825706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational physiotherapy group
Description: 20 patients with hemophilia were randomly allocated to an educational intervention or to a control group. The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
Study: NCT02381717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultra-sound guide
Description: Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Study: NCT01439971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280602
Description: 0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280602
Description: 4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280602
Description: 9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280602
Description: 18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280602
Description: 30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
Study: NCT03325348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Description: Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: IV labetalol 20 mg \& mint tablet will be given to patients every 15 min until one hour
Study: NCT00578877

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SILCS Diaphragm
Description: SILCS Diaphragm used with 5 ml gel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SILCS Diaphragm
Description: SILCS Diaphragm used with 5 ml gel

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nonoxynol-9 Gel
Description: Gynol II (2% N-9 gel)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Buffer Gel
Description: Buffer Gel
Study: NCT01468233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pre-filled syringe, administered by subcutaneous injection
Study: NCT02323685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SANGUINATE™
Description: Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
Study: NCT03706742

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed outreach
Description: The investigators will randomize all baby boomer patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
Study: NCT03363087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mapping and ablation
Description: Ultra high density scar mapping Collection of impedance data during ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mapping and ablation
Description: Ultra high density scar mapping Collection of impedance data during ablation
Study: NCT05748028

Intervention type: OTHER
Intervention: Rehabilitation
Description: All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.

Intervention type: OTHER
Intervention: Rehabilitation
Description: All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.

Intervention type: OTHER
Intervention: Administration of Clinical scales
Description: All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.

Intervention type: OTHER
Intervention: Administration of Clinical scales
Description: All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.